COVID-19 Vaccine Janssen becomes 4th backed for authorization by EMA

11 March 2021

Marking the fourth vaccine to be recommended for the prevention of the novel coronavirus by the European Medicines Agency, the EMA today revealed it has recommended granting a conditional marketing authorization for COVID-19 Vaccine Janssen in people from 18 years of age.

After a thorough evaluation, the EMA’s human medicines committee, CHMP, concluded by consensus that the data on the vaccine were robust and met the criteria for efficacy, safety and quality.

Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s vaccine thus joins Pfizer (NYSE: PFE)/BioNTech (Nasdaq: BNTX), AstraZeneca (LSE: AZN)/Oxford and Moderna (Nasdaq: RMNA) in gaining approval for their covid jabs, with this coming on the first anniversary of the World Health Organization declaring the pandemic on March 11, 2020.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK